

Pimitespib: Adis Evaluation

Key Points

- An orally available heat shock protein 90 (HSP90) inhibitor is being developed by Taiho Pharmaceutical for the treatment of solid tumours, including gastrointestinal stromal tumour (GIST)
- Received its first approval on 20 June 2022 in Japan
- Approved for GIST that has progressed after chemotherapy

Summary

Pimitespib (Jeselhy®) is an oral small molecule inhibitor of the α and β isoforms of HSP90. HSP90 α and HSP90 β regulate the stability and activity of a number of proteins that are crucial for tumour development.

Pimitespib is being developed by Taiho Pharmaceutical for the treatment of solid tumours, including GIST, and in June 2022 it received its first approval in Japan for GIST that has progressed after chemotherapy.

Pimitespib is undergoing phase I development for the treatment of solid tumours in the EU and the USA.

This summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © Springer Nature Switzerland AG 2022.